Morbidity and mortality on combination versus monotherapy: A posthoc analysis of the Systolic Hypertension in Europe trial

Journal of Hypertension

Volumn 28, Issue 4, 2010, Pages 865-874

  Thijs, Lutgarde ^a   Richart, Tom ^a,b   De Leeuw, Peter W ^b   Kuznetsova, Tatiana ^a   Grodzicki, Tomasz ^c   Kawecka Jaszcz, Kalina ^c   O'Brien, Eoin ^d   Redón, Josep ^e   Birkenhäger, Willem H ^f   Fagard, Robert ^a   Staessen, Jan A ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY OF VALENCIA   (Spain)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Antihypertensive treatment; Blood pressure; Enalapril; Isolated systolic hypertension; Nitrendipine

Indexed keywords

ENALAPRIL; HYDROCHLOROTHIAZIDE; NITRENDIPINE; PLACEBO;

AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EUROPE; FEMALE; FOLLOW UP; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; NEOPLASM; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME;

EID: 77952492993     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833627c9     Document Type: Article

References (30)

1. Bonita R, Reddy S, Galbraith S, Bettcher D, MacIntyre M, Peden M, et al. Neglected global epidemics: three growing threats. In: Beaglehole R, Irwin A, Prentice T, editors. The World Health Report 2003: shaping the future. Geneva, Switzerland: World Health Organization; 2003. pp. 83-102.
2. Weinehall L, Öhgren B, Persson M, Stegmayr B, Boman K, Hallmans G, et al. High remaining risk in poorly treated hypertension: the 'rule of halves' still exist. J Hypertens 2002; 20:2081-2088.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
4. Chobanian AV, Bakris GL, Black BK, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
5. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165:1147-1152.
6. Amery A, Birkenhäger W, Bulpitt CJ, Clement D, de Leeuw P, Dollery CT, et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging Clin Exp Res 1991; 3:287-302.
7. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
8. Staessen JA, Thijs L, Fagard RH, Birkenhäger WH, Arabidze G, Babeanu S, et al. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998; 32:410-416.
9. Staessen JA, Thijs L, Fagard R, Celis H, Birkenhäger WH, Bulpitt CJ, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22:847-857.
10. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet Care 1999; 22 (Suppl 1):S5-S19.
11. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an amlodipine±perindopril strategy compared with an atenolol±thiazide strategy. The Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
12. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
13. Thomas MC, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr, Smith NL, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008; 21:1111-1116.
14. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study. Am J Hypertens 1997; 10:697-704.
15. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Longterm persistence in statin therapy in the elderly. JAMA 2002; 288:455-461.
16. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (Suppl):2-6.
17. Blonde L, Wogen J, Kreilic C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5:424-431.
18. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122:290-300.
19. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427-1434.
20. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 1987; 10 (Suppl 1):S583-S585.
21. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007; 67:1309-1327.
22. Zanchetti A. Nitrendipine and ACE inhibitors. J Cardiovasc Pharmacol 1988; 12 (Suppl 4):S80-S85.
23. Osswald H, Mühlbauer B. The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens 1995; 13 (Suppl 2):S21-S28.
24. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30:587-604.
25. Belonje AM, Westenbrink BD, Voors AA, von Heahling S, Ponikowski P, Anker SD, et al. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. Am Heart J 2009; 157:91-96.
26. Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML, on behalf of the EUROPA investigators. Effects of perindopril on long-term clinical outcome of patients with coronary heart disease and preserved left ventricular function. Int J Cardiol 2007; 14:57-61.
27. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA, on behalf of the Action (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23:641-648.
28. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360-1369.
29. de la Sierra A, Roca-Cusachs A, Redón J, Marín R, Luque M, de la Figuera M, et al. Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients. Clin Drug Invest 2009; 29:459-469.
30. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The cycle repeats. Drugs 2002; 62:443-462.